[1] Jungnickel, P.W. Clin. Ther. 2000, 22 (11): 1268–1293. [2] Horrn, J. Clin. Ther. 2000, 22 (3): 266–280. [3] Avner, D.L. Clin. Ther. 2000, 22 (10): 1169–1185. [4] WHO Expert Committee, Guidelines for good clinical practice (GCP) for trials on pharmaceutical products, the use of essential drugs. Sixth report of the WHO Export Committee, WHO Technical Report Series, No. 850, 1995. [5] FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER) (2001), this article can be found online at http: //fda.gov/cder/guidance /index.htm. [6] State Committee of Pharmacopoeia. Guidance for evaluation of bioavailability and bioequivalence of pharmaceutical preparations in human. ChP, 193 (2005), Chemical Industry Press: Beijing, 2005. [7] Shi, S.J.; Li, Z.F.; Han, Z.M.; Chen, H.T.; Zeng, F.D. Chin. J. Clin. Pharmacol. 2006, 22 (5): 349–352. [8] Li, Z.J.; Lei, J.P.; Wu, C.F.; Pei, Q.; Liu, S.K. China Pharmacist. 2006, 9 (9): 797–799. [9] Jiao, X.L.; Duan, J.L.; Si, K.Y.; Huang, X.F.; Liu, D.L.; Yan, B.X. Chin. Pharm. J. 1999, 34 (7): 483–485. [10] Zhou, X.M.; Liu, J.; Gao, J.; Xu, L.X.; Jiang, L.M.; Li, F.C. Chin. New Drugs J. 2006, 15(12): 1008–1010. [11] Jian, L.Y.; Qiu, F.; Zhao, L.M.; Sun, Y.X.; Xu, Y.H. Chin. J. Clin Pharmacol. 2005, 21 (3): 213–216. [12] Lv, M.; Liu, D.K. Liaoning Pharm. Clin. Rem. 1999, 2 (3): 28–29. [13] Ramakrishna, N.V.S.; Vishwottam, K.N.; Wishu, S.; Koteshwara, M. J. Chromatogr. B. Analyt. Technol. Biomed. Lift Sci. 2005, 822: 326–329. |